D. E. Shaw & Co., Inc. Krystal Biotech, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 9,346 shares of KRYS stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,346

Holding current value

$1.45 Million

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$174.7 - $213.66 $296,990 - $363,222	-1,700 Reduced 15.39%	9,346 $1.7 Million
Q2 2024 Aug 14, 2024	SELL	$153.12 - $183.64 $10.9 Million - $13 Million	-70,981 Reduced 86.53%	11,046 $2.03 Million
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $1.61 Million - $2.67 Million	14,886 Added 22.17%	82,027 $14.6 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $1.09 Million - $1.46 Million	11,384 Added 20.42%	67,141 $8.33 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $4.99 Million - $5.99 Million	45,962 Added 469.24%	55,757 $6.47 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $329,616 - $547,344	4,200 Added 75.07%	9,795 $1.15 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $58,273 - $67,837	-805 Reduced 12.58%	5,595 $447,000
Q4 2022 Feb 14, 2023	SELL	$63.14 - $79.9 $107,338 - $135,830	-1,700 Reduced 20.99%	6,400 $507,000
Q2 2022 Aug 15, 2022	BUY	$48.93 - $73.47 $209,958 - $315,259	4,291 Added 112.65%	8,100 $532,000
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $198,029 - $274,666	3,809 New	3,809 $253,000
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $540,261 - $1.2 Million	-13,571 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $329,275 - $454,375	6,331 Added 87.44%	13,571 $709,000
Q2 2021 Aug 16, 2021	BUY	$62.14 - $81.82 $449,893 - $592,376	7,240 New	7,240 $492,000

Others Institutions Holding KRYS

# of Institutions

307

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.97B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account